Personale docente

Full Professor of General Pathology at the University of Parma. Head Unit of Experimental Oncology of the Department of Medicine and Surgery, University of Parma. Several periods of study and research at the Unit for Viral Oncology (Prof. Luc Montagnier), Institute Pasteur, Paris. Member of the Advisory Board of Novartis Italia Oncology. Member of the Editorial Advisory Board of Plos One as Academic Editor. Reviewer for: Molecular Cancer Therapeutics, PLOS One, Cythotherapy, Cancer Cell International, JTM, Molecular Carcinogenesis, Cancer Research. Member of: American Society for Investigative Pathology, European Association for Cancer Research, Italian Cancer Society, Italian Pathology Society, Cellular Biology and Differentiation Society. Head of the Scientific Committee of the Associazione Chiara Tassoni for the Research on Leukemia and cancer and Head of the Scientific Committee of the Associazione “Augusto per la Vita”. Chairman of the Scientific Committee 06 (Medical Sciences) and Member of the University Research Commission. Delegate of the Director of the Department of Medicine and Surgery at the Third Mission and Private Research. The scientific interest is focused on Translational Molecular Oncology in lung and breast cancer and malignant pleural mesothelioma. In particular he has been involved in the exploration of the efficacy of new therapeutic strategies in pre-clinical models, both in-vitro and in xenotransplanted nude mice. Principal Investigators and Co-investigator of the following grants:
Head of the Research Unit participating in the project: "Molecular targets in the therapy of non-small lung cancer" supported by Ministero della Salute
Head of the Research Unit participating in the project: "Biological predictive factors of response to target therapies in lung cancer" supported by Ministero della Salute
P.I. of the EFSA grant “Comparison between 3-MCPD and its palmitic esters in a 90-day toxicological study”
Coordinator of the preclinical study of the project: “Optimizing EGFR inhibitor treatment in non small cell lung cancer” funded by AIRC (P.I. Andrea Ardizzoni)
Coordinator of the preclinical study of the project: “Novel molecularly targeted approaches in the treatment of Squamous Cell Cancer of the Lung” funded by AIRC (P.I. Andrea Ardizzoni)
Coordinator of the preclinical study of the project: “Study of PD-L1 and other immunotherapy efficacy predictors on cytology and circulating tumor cells in advanced NSCLC” funded by AIRC (P.I. Andrea Ardizzoni)
Coordinator of the preclinical study of the project: “Beyond third-generation TKI in EGFR mutated NSCLC: resistance mechanisms, novel combinations and synthesis of new agents” funded by AIRC (P.I. Marcello Tiseo)
P.I. of the study: “Anti-tumor activity and molecular mechanisms of NVP-BGJ398 in NSCLC: studies in vitro and in xenotransplanted nude mice” supported by Novartis Farma
P.I. of the study: “Effect of BKM120 and BYL719 alone or in combination with EGFR TK inhibitors in NSCLC cell lines” supported by Novartis Farma
P.I. of the study: “Characterization of gefitinib uptake, metabolism and efflux in NSCLC cell lines to overcome gefitinib resistance” supported by AstraZeneca S.p.A.
P.I. of the study: “Differential expression of ErbB family of receptor tyrosine kinases and sensitivity to letrozole in breast cancer cell lines “ supported by Novartis Farma
P.I. of the study: “New therapeutic strategies for malignant pleural mesothelioma” supported by Chiesi Farmaceutici S.P.A. and private Associations.
Co-Author of 114 papers published on peer-reviewed international journals (total citations 1636 and total H-index 27, Scopus).
Patents:
Alfieri R., Bordi F., Carmi C, Cavazzoni A., Lodola A, Mor M, Petronini PG, Vezzosi S. Composti inibitori irreversibili di EGFR con attività antiproliferativa PCT/IB2009/055980
Alfieri R., Bordi F., Carmi C, Cavazzoni A., Lodola A, Mor M, Petronini PG, Vezzosi S. Composti inibitori irreversibili di EGFR con attività antiproliferativa PCT/IB2009/055980